<DOC>
	<DOCNO>NCT00825162</DOCNO>
	<brief_summary>A Phase IV , Open Label , Multi-Centre Study Evaluate Safety Tolerability Profile CSL Limited 's Influenza Virus Vaccine Paediatric Population Aged &gt; = 6 Months &lt; 18 Years</brief_summary>
	<brief_title>Safety Study CSL Limited 's Influenza Virus Vaccine Paediatric Population Aged &gt; = 6 Months &lt; 18 Years</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female participant age ≥ 6 month &lt; 18 year time vaccination ; 2 . Written inform consent participate study adherence protocol requirement . Consent obtain participant , parent guardian appropriate accord applicable Independent Ethics Committee ( IEC ) local requirement . Participant assent also obtain require applicable IEC ; 3 . Good health , determine medical history , target physical examination ; 4 . For participant age &lt; 9 year , bear normal gestation period ( 36 42 week ) ; 5 . Females childbearing potential ( define experience first menstrual cycle ) must abstinent use adequate contraceptive precaution e.g . intrauterine contraceptive device , oral contraceptive , equivalent hormonal contraception ( e.g. , progestogenonly implant , vaginal contraceptive ring , cutaneous hormonal patch injectable contraceptive ) least 2 month vaccination . Females age ≥ 9 year must also return negative urine pregnancy test enrolment . 1 . Known hypersensitivity previous dose influenza vaccine allergy egg , chicken protein , neomycin , polymyxin , component Study Vaccine ; 2 . Clinical sign significant active infection and/or elevate temperature ( ≥ 38.0°C oral ≥ 37.5°C axillary ) study entry ; 3 . Vaccination influenza virus previous 6 month seasonal IVV ; 4 . Vaccination experimental IVV ( e.g . candidate pandemic IVV novel IVV ) previous 6 month ; 5 . Females child bear potential , plan become pregnant planning discontinue contraceptive precaution within 2 month vaccination ; 6 . Pregnant lactating female ; 7 . Clinically significant medical psychiatric condition , follow : For acute condition ( active recent ) , condition require hospitalisation within last month ; For chronic condition : Investigator feel chronic condition unstable , illness exacerbation within previous month : i. require hospitalisation ; ii . significant organ function deterioration ; iii . major change treatment dosage ; iv . require major new treatment ; The Investigator feel participant clinical condition may adversely affect study participation . 8 . Confirmed suspected immune deficiency ( congenital acquire , include cancer human immunodeficiency virus infection ) ; 9 . History seizure , exception past history single seizure event age two year previously ; 10 . Known history GuillainBarré Syndrome ; 11 . Current treatment radiotherapy cytotoxic drug , treatment within 6 month prior administration Study Vaccine ; 12 . Current ( within 90 day prior receive Study Vaccine ) immunosuppressive immunomodulative therapy , include systemic corticosteroid , follow : • Chronic long term corticosteroid : . Age le 9 year : ≥ 0.5 mg/kg/day oral prednisolone equivalent daily ; ii . Age 9 year : ≥ 15 mg/day oral prednisolone equivalent daily ; • Sporadic corticosteroid : . Age le 9 year : ≥ 1 mg/kg/day oral prednisolone equivalent 2 short course &gt; 3 day 3 month precede vaccination ; ii . Age 9 year : ≥ 40 mg/day oral prednisolone equivalent two short course &gt; 3 day 3 month precede vaccination ; Note : Use topical inhalant corticosteroid prior administration Study Vaccine throughout Study acceptable 13 . Administration immunoglobulins and/or blood product within 3 month precede administration Study Vaccine study ; 14 . Current treatment warfarin anticoagulant ; 15 . Participation clinical trial use investigational compound ( i.e . new chemical biological entity register clinical use ) within 90 day prior receive Study Vaccine entry study study period ; 16 . Evidence , history ( within previous 12 month ) drug alcohol abuse ; 17 . If , Investigator 's opinion , participant take part clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>